Special commentary: Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices

Kristen L. Meier, David Greenfield, Gene Hilmantel, Malik Y. Kahook, Carol Lin, Eva M. Rorer, Kuldev Singh, Michelle E. Tarver, Robert N. Weinreb, Malvina B. Eydelman, Jeffrey M. Liebmann

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This workshop facilitated discussion among clinicians, researchers, industry, and regulators about the challenging issues posed by the rapid innovations in the OCT device area, and identified many questions that remain unanswered. Both the American Glaucoma Society and the FDA hope that further work will be conducted in this area to advance the missions of both organizationsdto promote excellence in the care of patients with glaucoma and protect and promote public health. With the assistance of the speakers, panelists, and attendees of the workshop, clinical and regulatory issues surrounding diagnostic imaging devices for glaucoma and approaches to evaluate the accuracy, agreement, and precision of measurements were elucidated. In addition, the workshop advanced the regulatory science that forms the basis for shaping FDA recommendations for OCT to facilitate efficient delivery of innovative and effective imaging technologies to the US market. By discussing the benefits, limitations, and future directions of these imaging technologies and their reference databases, we hope to enhance their proper use in clinical practice as well as stimulate further advances in their development and evaluation.

Original languageEnglish
Pages (from-to)2116-2123
Number of pages8
JournalOphthalmology
Volume121
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

United States Food and Drug Administration
Reproducibility of Results
Glaucoma
Education
Equipment and Supplies
Technology
Diagnostic Imaging
Patient Care
Industry
Public Health
Research Personnel
Databases

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Special commentary : Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices. / Meier, Kristen L.; Greenfield, David; Hilmantel, Gene; Kahook, Malik Y.; Lin, Carol; Rorer, Eva M.; Singh, Kuldev; Tarver, Michelle E.; Weinreb, Robert N.; Eydelman, Malvina B.; Liebmann, Jeffrey M.

In: Ophthalmology, Vol. 121, No. 11, 01.01.2014, p. 2116-2123.

Research output: Contribution to journalArticle

Meier, KL, Greenfield, D, Hilmantel, G, Kahook, MY, Lin, C, Rorer, EM, Singh, K, Tarver, ME, Weinreb, RN, Eydelman, MB & Liebmann, JM 2014, 'Special commentary: Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices', Ophthalmology, vol. 121, no. 11, pp. 2116-2123. https://doi.org/10.1016/j.ophtha.2014.05.024
Meier, Kristen L. ; Greenfield, David ; Hilmantel, Gene ; Kahook, Malik Y. ; Lin, Carol ; Rorer, Eva M. ; Singh, Kuldev ; Tarver, Michelle E. ; Weinreb, Robert N. ; Eydelman, Malvina B. ; Liebmann, Jeffrey M. / Special commentary : Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices. In: Ophthalmology. 2014 ; Vol. 121, No. 11. pp. 2116-2123.
@article{f5dc97d114d24cda8ec7798cbece998f,
title = "Special commentary: Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices",
abstract = "This workshop facilitated discussion among clinicians, researchers, industry, and regulators about the challenging issues posed by the rapid innovations in the OCT device area, and identified many questions that remain unanswered. Both the American Glaucoma Society and the FDA hope that further work will be conducted in this area to advance the missions of both organizationsdto promote excellence in the care of patients with glaucoma and protect and promote public health. With the assistance of the speakers, panelists, and attendees of the workshop, clinical and regulatory issues surrounding diagnostic imaging devices for glaucoma and approaches to evaluate the accuracy, agreement, and precision of measurements were elucidated. In addition, the workshop advanced the regulatory science that forms the basis for shaping FDA recommendations for OCT to facilitate efficient delivery of innovative and effective imaging technologies to the US market. By discussing the benefits, limitations, and future directions of these imaging technologies and their reference databases, we hope to enhance their proper use in clinical practice as well as stimulate further advances in their development and evaluation.",
author = "Meier, {Kristen L.} and David Greenfield and Gene Hilmantel and Kahook, {Malik Y.} and Carol Lin and Rorer, {Eva M.} and Kuldev Singh and Tarver, {Michelle E.} and Weinreb, {Robert N.} and Eydelman, {Malvina B.} and Liebmann, {Jeffrey M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2014.05.024",
language = "English",
volume = "121",
pages = "2116--2123",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Special commentary

T2 - Food and drug administration and American glaucoma society co-sponsored workshop: The validity, reliability, and usability of glaucoma imaging devices

AU - Meier, Kristen L.

AU - Greenfield, David

AU - Hilmantel, Gene

AU - Kahook, Malik Y.

AU - Lin, Carol

AU - Rorer, Eva M.

AU - Singh, Kuldev

AU - Tarver, Michelle E.

AU - Weinreb, Robert N.

AU - Eydelman, Malvina B.

AU - Liebmann, Jeffrey M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This workshop facilitated discussion among clinicians, researchers, industry, and regulators about the challenging issues posed by the rapid innovations in the OCT device area, and identified many questions that remain unanswered. Both the American Glaucoma Society and the FDA hope that further work will be conducted in this area to advance the missions of both organizationsdto promote excellence in the care of patients with glaucoma and protect and promote public health. With the assistance of the speakers, panelists, and attendees of the workshop, clinical and regulatory issues surrounding diagnostic imaging devices for glaucoma and approaches to evaluate the accuracy, agreement, and precision of measurements were elucidated. In addition, the workshop advanced the regulatory science that forms the basis for shaping FDA recommendations for OCT to facilitate efficient delivery of innovative and effective imaging technologies to the US market. By discussing the benefits, limitations, and future directions of these imaging technologies and their reference databases, we hope to enhance their proper use in clinical practice as well as stimulate further advances in their development and evaluation.

AB - This workshop facilitated discussion among clinicians, researchers, industry, and regulators about the challenging issues posed by the rapid innovations in the OCT device area, and identified many questions that remain unanswered. Both the American Glaucoma Society and the FDA hope that further work will be conducted in this area to advance the missions of both organizationsdto promote excellence in the care of patients with glaucoma and protect and promote public health. With the assistance of the speakers, panelists, and attendees of the workshop, clinical and regulatory issues surrounding diagnostic imaging devices for glaucoma and approaches to evaluate the accuracy, agreement, and precision of measurements were elucidated. In addition, the workshop advanced the regulatory science that forms the basis for shaping FDA recommendations for OCT to facilitate efficient delivery of innovative and effective imaging technologies to the US market. By discussing the benefits, limitations, and future directions of these imaging technologies and their reference databases, we hope to enhance their proper use in clinical practice as well as stimulate further advances in their development and evaluation.

UR - http://www.scopus.com/inward/record.url?scp=84908470958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908470958&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.05.024

DO - 10.1016/j.ophtha.2014.05.024

M3 - Article

C2 - 25085628

AN - SCOPUS:84908470958

VL - 121

SP - 2116

EP - 2123

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -